Authors
Latest:
Monitoring and Follow-Up of Patients with Chronic GVHDThe panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.
Latest:
Dr. Iacovelli on Eligibility Criteria of the ARIES Trial in Urothelial CancerRoberto Iacovelli, MD, PhD, discusses the patient eligibility criteria of the phase 2 ARIES trial in urothelial cancer.
Latest:
Dr Masarova on the Investigation of Ropeginterferon Alfa in Essential ThrombocythemiaLucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.
Latest:
Dr Iyer on the Mechanism of Action of Imetelstat in Lower-Risk MDSSunil Iyer, MD, discusses the mechanism of action of imetelstat in patients with lower-risk myelodysplastic syndrome with anemia.
Latest:
Dr Cigliola on Potential Implications of the SURE-01 and SURE-02 Trials in MIBCAntonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.
Latest:
Dr Baik on the Clinical Utility of Zongertinib in Previously Treated HER2-Mutant NSCLCChristina S. Baik, MD, MPH, discusses the clinical utility of zongertinib in previously treated non–small cell lung cancer harboring HER2 TKD mutations.
Latest:
Dr Creelan on the Promise of Cemiplimab in Squamous NSCLCBen Creelan, MD, discusses survival outcomes with cemiplimab in patients with squamous non–small cell lung cancer.
Latest:
Dr Hacker on the Proportion of HER2-Expressing Tumors in Endometrial CancerKari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.
Latest:
Dr Lathan on Community-based Cancer Evaluation Services in Underserved Patient GroupsChristopher Lathan, MD, MS, MPH, discusses socioeconomical and clinical findings from a clinical outreach program incorporating cancer diagnostic services and patient navigation for patients from traditionally underserved populations.
Latest:
Dr Growdon on the Withdrawal of Later-Line Indication For Olaparib in BRCA-Mutated Ovarian CancerWhitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.
Latest:
Dr Baldonado on the Evolution of Targeted Therapy in NSCLCJobelle Baldonado, MD, discusses the evolution of personalized approaches to treatment in non–small cell lung cancer.
Latest:
Dr. Nguyen on the Efficacy of IS-002 for Robotic Prostatectomy in Prostate CancerHao G. Nguyen MD, PhD, discusses the efficacy and safety of IS-002, a prostate-specific membrane antigen–targeting fluorophore, for image-guided surgery in patients with prostate cancer undergoing robotic prostatectomy.
Latest:
Dr Narayan on the Evolving Treatment Paradigm in Metastatic Urothelial CarcinomaVivek K. Narayan, MD, MS, discusses potential avenues for treatment considerations in patients with metastatic urothelial carcinoma.
Latest:
Dr Bewersdorf on Ruxolitinib Plus Abemaciclib in MyelofibrosisJan Bewersdorf, MD, discusses the design of an ongoing phase 1 trial investigating ruxolitinib plus abemaciclib in patients with primary or secondary myelofibrosis.
Latest:
Dr. Sheffield on the Economic Cost of Delaying of Treatment in NSCLCBrandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.
Latest:
HR+ Breast Cancer: Role of RxPONDER Data in Clinical PracticeLajos Pusztai, MD, PhD, and Priyanka Sharma, MD, share closing thoughts on additional data they hope to see from the RxPONDER trial, and using these data in clinical practice for the treatment of HR+ early breast cancer.
Latest:
Supportive Care and Medication Access in GvHDHana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.
Latest:
Dr Liu on the Use of PSMA PET to Inform Lymph Node Dissection in Prostate CancerJen-Jane Liu, MD, discusses how prostate-specific membrane antigen PET imaging may help inform lymph node dissection in the localized disease setting for patients with prostate cancer.
Latest:
Dr Sandhu on a Pooled Analysis of the FELIX Trial in Relapsed/Refractory B-ALLKaramjeet Singh Sandhu, MD, discusses outcomes from a pooled analysis of the FELIX study in relapsed/refractory B-cell acute lymphoblastic leukemia.
Latest:
Future Directions in the Management of Hepatocellular CarcinomaTo close, Dr. Saeed and Dr. Singal share their excitement for the future landscape, emerging agents and treatment strategies for patients with HCC.
Latest:
Dr. Milner on Hematopoietic Stem Cell Transplant in Aplastic AnemiaJordan B. Milner, MD, discusses findings from a study evaluating the use of hematopoietic stem cell transplant up front or as salvage therapy after unsuccessful immunosuppressive therapy in pediatric patients with severe aplastic anemia.
Latest:
Rapid Readouts: Results from the Phase 3 VISION StudyA. Oliver Sartor, MD, presents data from the American Society of Clinical Oncology 2021 annual meeting from the VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Latest:
CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through AccountabilityAlthough the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.
Latest:
Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer LandscapeA panel of experts offer future perspectives in HR+ breast cancer.
Latest:
Advice for New Nurse Practitioners Working With Patients With Endometrial CancerClosing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.
Latest:
Dr Daver on the Initial Safety of DSP-5336 in Relapsed/Refractory Acute LeukemiaNaval G. Daver, MD, discusses updated findings from a phase 1/2 study of the menin-MLL inhibitor DSP-5336 in relapsed/refractory acute leukemias.
Latest:
Student Loan Debt, Immigration Status Often Drive Career Decisions for FellowsInvestigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.
Latest:
Dr Ziegler on Tovorafenib in Pediatric Low-Grade GliomaDavid Ziegler, MD, PhD, discusses findings from the phase 2 FIREFLY-1 trial of tovorafenib in pediatric patients with low-grade glioma.
Latest:
Dr Iams on the Impact of Adagrasib on Patient Outcomes in KRAS G12C–Mutant NSCLCWade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.
Latest:
Ahuno on Bringing Precision Medicine in Cancer Care to GhanaSamuel Ahuno discusses bringing precision medicine in cancer care to Ghana.
